Last reviewed · How we verify

Enzalutamide, Abiraterone — Competitive Intelligence Brief

Enzalutamide, Abiraterone (Enzalutamide, Abiraterone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen receptor antagonist + CYP17A1 inhibitor combination. Area: Oncology.

phase 3 Androgen receptor antagonist + CYP17A1 inhibitor combination Androgen receptor (AR) and CYP17A1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Enzalutamide, Abiraterone (Enzalutamide, Abiraterone) — Veru Inc.. This combination of an androgen receptor antagonist (enzalutamide) and a CYP17A1 inhibitor (abiraterone) blocks testosterone production and androgen signaling to treat hormone-sensitive prostate cancer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Enzalutamide, Abiraterone TARGET Enzalutamide, Abiraterone Veru Inc. phase 3 Androgen receptor antagonist + CYP17A1 inhibitor combination Androgen receptor (AR) and CYP17A1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen receptor antagonist + CYP17A1 inhibitor combination class)

  1. Veru Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enzalutamide, Abiraterone — Competitive Intelligence Brief. https://druglandscape.com/ci/enzalutamide-abiraterone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: